In the past, Joe had assisted Joanne at City of Hope with other projects.
All who can, or care to participate, please e-mail your opinion responses to Joanne at the e-mail address listed below.
From City of Hope:
We are developing an PET imaging agent that identifies HER2 positive breast cancer. The agent is Herceptin with a radiation particle on it. Our goal is to use this agent to predict which women with metastatic breast cancer are likely to benefit from T-DM1.
From a patient’s perspective it this a meaningful test? And if so why?
We have found that some women with metastatic breast cancer also pick up the tracer. This may mean that breast cancers all have a little HER2 or that the way we measure HER2 is not always accurate. We are asking women with HER2 negative breast cancer to participate in the imaging study.
Will women participate?
Is it reasonable to ask women to undergo a biopsy of an area that was particularly positive for HER2 uptake?
We suspect that women with a positive PET image (using this Herceptin imagine agent) may benefit from T-DM1. Will women with HER2 negative breast cancers that are positive on this PET imaging participate in a treatment trial of T-DM1?
Please e-mail your responses to
jmortimer@coh.org
Many thanks!
Joanne Mortimer, M.D., F.A.C.P.
Director, Womens Cancers Program
Vice Chair Medical Oncology
Associate Director for Affiliate Programs
Professor, Division of Medical Oncology & Experimental Therapeutics
City of Hope Comprehensive Cancer Center
1500 East Duarte Road
Duarte, CA 91010
626-256-HOPE (ext 61200)
626-930-5362 (FAX)
Abhishek Chandiramani, Program Manager
ext 61218